Capsaicin - Centrexion Therapeutics

Drug Profile

Capsaicin - Centrexion Therapeutics

Alternative Names: 4975; Adlea; ALGRX-4975; CNTX-4975; VLNX-4975

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Johns Hopkins University
  • Developer Anesiva; Centrexion Therapeutics
  • Class Antipruritics; Catechols; Local anaesthetics; Monounsaturated fatty acids; Non-opioid analgesics; Polyunsaturated alkamides; Small molecules
  • Mechanism of Action TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuropathic pain
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Neuropathic pain
  • New Molecular Entity No

Highest Development Phases

  • Phase II Neuropathic pain; Pain
  • Discontinued Postoperative pain

Most Recent Events

  • 13 Dec 2016 Efficacy data and adverse event dat from a phase IIb trial in Post-operative pain (osteoarthritis) released by Centrexion Therapeutics
  • 15 Nov 2016 Capsaicin - Centrexion Therapeutics receives Fast Track designation for Neuropathic pain [Parenteral,Injection] in USA
  • 15 Nov 2016 Centrexion plans phase III trial of capsaicin in Neuropathic pain (Morton's neuroma)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top